MX2021014097A - Composiciones de vacunas para clostridium difficile. - Google Patents
Composiciones de vacunas para clostridium difficile.Info
- Publication number
- MX2021014097A MX2021014097A MX2021014097A MX2021014097A MX2021014097A MX 2021014097 A MX2021014097 A MX 2021014097A MX 2021014097 A MX2021014097 A MX 2021014097A MX 2021014097 A MX2021014097 A MX 2021014097A MX 2021014097 A MX2021014097 A MX 2021014097A
- Authority
- MX
- Mexico
- Prior art keywords
- tcdb
- immunogens
- gtd
- cdi
- cpd
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000193163 Clostridioides difficile Species 0.000 title abstract 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229930186900 holotoxin Natural products 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851040P | 2019-05-21 | 2019-05-21 | |
| PCT/US2020/034070 WO2020237090A1 (en) | 2019-05-21 | 2020-05-21 | Vaccine compositions for clostridium difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014097A true MX2021014097A (es) | 2022-03-11 |
Family
ID=73458679
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014097A MX2021014097A (es) | 2019-05-21 | 2020-05-21 | Composiciones de vacunas para clostridium difficile. |
| MX2026001281A MX2026001281A (es) | 2019-05-21 | 2021-11-17 | Composiciones de vacunas para clostridium difficile |
| MX2026001280A MX2026001280A (es) | 2019-05-21 | 2021-11-17 | Composiciones de vacunas para clostridium difficile |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026001281A MX2026001281A (es) | 2019-05-21 | 2021-11-17 | Composiciones de vacunas para clostridium difficile |
| MX2026001280A MX2026001280A (es) | 2019-05-21 | 2021-11-17 | Composiciones de vacunas para clostridium difficile |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220062401A1 (https=) |
| EP (1) | EP3972638A4 (https=) |
| JP (1) | JP7637988B2 (https=) |
| CN (1) | CN114126644A (https=) |
| BR (1) | BR112021023119A2 (https=) |
| CA (1) | CA3141165A1 (https=) |
| MX (3) | MX2021014097A (https=) |
| WO (1) | WO2020237090A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| EP4658302A1 (en) * | 2023-02-02 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1000155A1 (en) * | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| WO2013084071A2 (en) * | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014086787A1 (en) * | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| WO2015123767A1 (en) * | 2014-02-18 | 2015-08-27 | The Hospital For Sick Children | Compositions and methods for treating or preventing clostridium infection |
| CA2976976C (en) * | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| WO2019143552A1 (en) * | 2018-01-16 | 2019-07-25 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
-
2020
- 2020-05-21 EP EP20810329.1A patent/EP3972638A4/en active Pending
- 2020-05-21 BR BR112021023119A patent/BR112021023119A2/pt unknown
- 2020-05-21 JP JP2021568804A patent/JP7637988B2/ja active Active
- 2020-05-21 WO PCT/US2020/034070 patent/WO2020237090A1/en not_active Ceased
- 2020-05-21 CA CA3141165A patent/CA3141165A1/en active Pending
- 2020-05-21 CN CN202080049940.3A patent/CN114126644A/zh active Pending
- 2020-05-21 MX MX2021014097A patent/MX2021014097A/es unknown
-
2021
- 2021-11-17 MX MX2026001281A patent/MX2026001281A/es unknown
- 2021-11-17 MX MX2026001280A patent/MX2026001280A/es unknown
- 2021-11-19 US US17/531,058 patent/US20220062401A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026001280A (es) | 2026-03-02 |
| JP2022532917A (ja) | 2022-07-20 |
| MX2026001281A (es) | 2026-03-02 |
| EP3972638A4 (en) | 2023-09-13 |
| US20220062401A1 (en) | 2022-03-03 |
| EP3972638A1 (en) | 2022-03-30 |
| BR112021023119A2 (pt) | 2022-01-25 |
| WO2020237090A1 (en) | 2020-11-26 |
| CN114126644A (zh) | 2022-03-01 |
| JP7637988B2 (ja) | 2025-03-03 |
| CA3141165A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
| EA201800444A1 (ru) | Производные майтанзиноида, их конъюгаты и способы использования | |
| SA518400103B1 (ar) | مستضد غشاء محدد للبروستات يستهدف عوامل الترابط الشديد للمعالجة الإشعاعية الداخلية لسرطان البروستات | |
| MX2020006168A (es) | Compuestos de 4-azaindol. | |
| MX2024015440A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| EA202091508A1 (ru) | 6-азаиндольные соединения | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| MX2026001281A (es) | Composiciones de vacunas para clostridium difficile | |
| EA201890175A1 (ru) | Антитела к cd40 | |
| BR112017023374A2 (pt) | formulação de anticorpo anti-cgrp | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| BR112018070013A2 (pt) | proteínas f do rsv pré-fusão solúveis estabilizadas | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| CR20170080A (es) | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| EA201000383A1 (ru) | Способ ингибирования клостридиум диффициле введением оритаванцина | |
| CO2017012988A2 (es) | Agentes, usos y métodos para el tratamiento | |
| EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| JOP20220255A1 (ar) | أجسام tau المضادة لـ phf المضاد واستخداماتها | |
| EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| BR112012018343A2 (pt) | "composições imunogênicas" | |
| BR112021025491A2 (pt) | Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático | |
| BR112023001615A2 (pt) | Tratamento para enxaqueca | |
| MX2018004938A (es) | Vacunas de antigeno ligado a pcrv de p. aeruginosa. |